You're signed outSign in or to get full access.
Bioimpact Capital LLC
BioImpact Capital LLC, also known as MPM BioImpact LLC, is a venture capital investment firm headquartered in Boston, Massachusetts. It specializes in biotechnology and life sciences, supporting the development of innovative therapies by investing in early- and late-stage biotech companies. The firm, previously known as MPM Oncology Impact Management LP, operates out of its Boston office and employs approximately 50 professionals, as reported in 2024. BioImpact Capital serves institutional clients, primarily through pooled investment vehicles, and has been active in the field under the MPM brand for multiple decades.
Investment Strategy
BioImpact Capital focuses on venture capital investing in biotechnology and life sciences, targeting companies with breakthrough therapies that have the potential to transform patient outcomes. The firm seeks investments across various stages of development, from early innovation to later-stage growth, aiming to leverage deep sector expertise and scientific rigor to identify and support high-impact enterprises. The strategy emphasizes partnerships with pioneering companies and teams in the biotech sector, and the creation of meaningful value through hands-on investment and company-building.
Latest 13F Filing Activity
Bioimpact Capital LLC filed their most recent 13F report on Jun 30, 2025 disclosing 44 equity positions with a total 13F market value of $577M. The fund increased holdings in Tarsus Pharmaceuticals Inc., Dyne Therapeutics, Inc., Akebia Therapeutics Inc. among other positions. Bioimpact Capital LLC reduced exposure to Lantheus Holdings Inc., United Therapeutics Corp., Iteos Therapeutics, Inc. among others.
Top Holdings
Equity Positions (44)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
C CGEM | Cullinan Therapeutics, Inc. | 9.98% | $57.6M | 7,648,268 | $41.67 | $7.53 | -$305.9K |
M MDGL | Madrigal Pharmaceuticals Inc | 5.27% | $30.4M | 100,415 | $331.23 | $302.64 | -$2.9M |
Z ZLAB | Zai Lab Ltd | 4.51% | $26.1M | 745,060 | $26.59 | $34.97 | -$4.1M |
G GH | Guardant Health Inc | 3.99% | $23.0M | 442,656 | $28.26 | $52.04 | +$4.2M |
S SPRY | ARS Pharmaceuticals Inc | 3.94% | $22.7M | 1,303,399 | $12.58 | $17.45 | +$6.2M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more